Immutep Ltd has released a press release.
Immutep receives IND approval from US FDA for IMP321
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep submits IND application with FDA
- Mid-point of patient enrolment reached in AIPAC trial
- Webcast slides for TACTI-mel clinical trial data
- Response to ASX Price Query
- Immutep raises A$6.85M through institutional placement
Later from Immutep
- TACTI-mel Patient Recruitment Complete & Operational Update
- Appendix 4E & 2018 Full Year Statutory Accounts
- Progress towards clinical development of IMP761
- Immutep enters into collaboration with Pfizer & Merck KGaA
- Positive interim TACTI-mel data presented at SITC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep